Introduction
Colorectal cancer, a significant cause of morbidity and mortality throughout the world, is due to the pathologic transformation of normal colonic epithelium to an adenomatous polyp and ultimately an invasive cancer. This multistep progression is associated with a number of recently characterized genetic alterations, including mutations of tumor-suppressor genes and proto-oncogenes, such as APC, K-ras, p53 or DCC. 1 Tumor-suppressor gene replacement therapy with wild-type p53 has been developed as a mechanismbased therapy. 2, 3 This therapy yielded antitumor effects in animal and cell culture experiments, but only partial effects in clinical trials. Other gene therapies for human colorectal cancer, such as enzyme/prodrug systems (HSVtk/ganciclovir; CD/5-fluorocytosine) and immune-gene therapy based on cytokine or tumor antigen expression to induce tumor immunity (eg CEA), have not yet improved prognosis. 4, [5] [6] [7] Elucidation of the basic molecular mechanisms of colorectal cancer and determination of a novel target for gene therapy are thus required.
Activator protein-1 (AP-1) is one of the transcriptional factors related to multiple gene transcription of mitogenic signal cascades. AP-1 is expressed in most types of cells and is composed of hetero-and homodimers of the Jun and Fos families. As recently reviewed, AP-1 exerts diverse biological effects on proliferation, transformation, differentiation and apoptosis, depending on cell type and surrounding environment. 8 AP-1 proteins, mostly those belonging to the Jun group, have also been suggested to control cell life and death through their ability to regulate the expression and function of cell cycle regulators, such as Cyclin D1, p53, p21(cip1/waf1), p19(ARF) and p16. 8 Although relatively little is known about the role of AP-1 activation in colorectal cancer growth, there are some reports indicating that AP-1 activation is related to colorectal cancer growth. [9] [10] [11] In contrast, other reports suggest that AP-1 is important for differentiation, apoptosis or resistance to therapy. Thus, the role of AP-1 in colorectal cancer has been controversial, and it remains to be determined whether AP-1 is essential for the multiplication of colorectal cancer.
In the present study, we constructed a recombinant adenovirus containing the dominant-negative mutant of c-Jun (Ad-DN-c-Jun) and infected it into colon cancer cells (HT-29) in vitro and in vivo to elucidate the roles of AP-1. We demonstrated that AP-1 was essential for colon cancer growth both in vitro and in vivo, and an important modulator of the cell cycle in HT-29 cells. We obtained the first evidence that DN-c-Jun gene transfer exhibited a significant antitumor effect on colon cancer both in vitro and in vivo, and demonstrated the possibility of AP-1-based gene therapy as a novel treatment of colorectal cancer.
Results

Induction of AP-1 DNA-binding activity in HT-29 cells
Electrophoretic mobility shift assay (EMSA) in Figure 1 shows that AP-1 DNA-binding activity in HT-29 cells increased the 1% serum stimulation in a time-dependent manner, and peaked 6 h later.
Efficiency of transfection of adenovirus in HT-29 cells
After infection at multiplicities of infection (MOI) of 3, 30 or 100 with Ad-LacZ, 30, 70 (Figure 2 ) or approximately 100% of the cells expressed LacZ gene (b-galactosidasepositive cells). These findings indicated that the number of cells expressing LacZ gene was dependent on MOI of Ad-LacZ, and that infection of MOI of 100 with Ad-LacZ was enough to transduce the gene to HT-29 cells.
Characteristics of AP-1 DNA-binding activity in HT-29 cells induced by Ad-DN-c-Jun infection
As shown in Figure 3a , infection with Ad-DN-c-Jun produced a new AP-1 DNA-binding activity (arrow 1) whose position was upper to that of the endogenous AP-1 band (arrow 2). On the other hand, control adenovirus did not change the pattern of AP-1 DNA-binding activity. As shown in Figure 3b , the bands due to Ad-DN-c-Jun (arrow 1) and endogenous AP-1 band (arrow 2) were found to indicate specific binding for AP-1, since the addition of unlabeled AP-1 oligonucleotide resulted in a decrease in the formation of AP-1 complex in a dosedependent manner. As shown by supershift analysis in Po0.05). Although there was a slight tendency of reduction of tumor volume by control adenovirus, no statistical difference in the tumor volume was found between both groups treated with control adenovirus and PBS. Thus, Ad-DN-c-Jun significantly inhibited the growth of xenografted HT-29 tumors (Figure 7 ). In this in vivo study, the administration of DN-c-Jun did not affect animal mortality, body weight or appetite (data not shown).
Evaluation of Ki-67 immunostaining of HT-29 cells in xenografted tumors
Immunoreactive Ki-67 cells were found in the xenografted tumors, and Ki-67 labeling index was measured by histological findings according to the described methods ( Figure 8 ). Ad-DN-c-Jun significantly decreased the labeling index compared with Ad-Luci (3871.0 versus 50.671.5%; Po0.01) (Figure 9 ).
Discussion
AP-1, a nuclear protein, is an important transcription factor regulating DNA transcription and gene expression. The mammalian AP-1 proteins are homo-and heterodimers composed of basic region-leucine zipper proteins including those of the Jun families (c-Jun, JunB and JunD) and Fos families (c-Fos, FosB, Fra-1 and Fra-2). 8 A variety of stimuli, including serum, growth factors and cytokines, induce AP-1 activity, and AP-1 activation is also reported to occur in cancer cells with Ras mutation. 15 Accumulating evidence suggests that AP-1 activity plays a role in cancer growth control. 16 Many reports suggest that elevated concentrations of fecal bile acids are associated with the promotion of colon cancer. [17] [18] [19] In these reports, Hirano et al 9 demonstrated that AP-1 is associated with the promotion of colon cancer induced by bile acids. Interestingly, however, other transcription factors such as NF-kappa B, Sp1 or ATF/CREB was not affected by bile acid. Thus, they suggested that AP-1 but not other transcription factors may be specific for colon cancer induction by bile acids. Glinghammar et al 10 also suggested that diluted lipid extracts from fecal water samples significantly induced AP-1-dependent gene transcription and induce cell proliferation. On the other hand, it has been proposed that AP-1 affects differentiation rather than multiplication, since AP-1 is highly activated during late progression of colon cancer. 20 Mandal et al 21 suggested that apoptosis triggered by butyric acid involves transcriptional stimulation of the Bax gene via the activation of the JNK/AP-1 pathway in colonic epithelial cells. Furthermore, Yao et al 22 reported the induction of AP-1 activity in human HT29 cells exposed to hypoxic conditions that was considered to cause the resistance to anticancer drugs. However, the biological and physiological functions of AP-1 in relation to the growth of cancer, in particular that of colorectal cancer, are not fully understood, and there is no report concerning direct blockade of AP-1 in colorectal cancer since no specific and potent pharmacological inhibitor of AP-1 is available. Many reports using adenovirus for in vivo studies suggested that adenovirus itself has a faint nonspecific cytotoxic effect. 26, 27 Importantly, however, no statistically significant decrease was found in the growth curves of control adenovirus compared to that with PBS in the present study. In addition, a significant effect by Ad-DNc-Jun on the growth curves was found compared to control adenovirus. All these findings suggest that the observed results of control adenovirus for tumor volume reduction must be due to the nonspecific responses derived from Ad vector.
It is also unclear whether c-Jun has the relation to the cell proliferation of normal colon cells in this study. However, the activation of AP-1 and expression of c-Jun are more increased in colon cancer cells than in normal cells. 28 Inhibition of c-Jun by Ad-DN-c-Jun should be more effective for proliferation of colon cancer cells than nonmalignant cells. On the other hand, adverse side effects of Ad-DN-c-Jun infection such as mortality, body weight loss and appetite loss were not apparent in the present study. These observations suggest that DN-c-Jun is a promising target for gene therapy of colon cancer. Generally, it is important that more effective localregional delivery system of target gene should be established not only to enhance the efficiency for tumor reduction, but also to avoid the nonspecific responses. Further investigation will be needed.
In conclusion, we obtained the first evidence that specific blockade of AP-1 by a dominant-negative mutant of c-Jun gene transfer prevented colon cancer growth both in vitro and in vivo. Our study provides new insights into the molecular mechanisms of colorectal cancer. AP-1 appears to be a novel target for gene therapy of colorectal cancer.
Materials and methods
Cells and culture conditions
The human colon adenocarcinoma cell line HT-29 was purchased from American Type Culture Collection. Cells were constantly grown as monolayers in McCoy's 5A medium, supplemented with 10% heat-inactivate fetal bovine serum (FBS) in a 5% CO 2 and 95% incubator atmosphere at 371C and subcultured every 7 days. 
LacZ gene transfer by Ad-LacZ in vitro
We evaluated LacZ gene expression by the X-gal staining method as described previously. 30 Briefly, 48 h after infection, HT-29 cells were washed with PBS and fixed in 2% (vol/vol) glutaraldehyde in PBS, pH 7.4 for 5 min at 41C. The cells were then washed and stained with X-gal solution (1 mg/ml 5-bromo-4-chloro-3-indolyl-bgal-actopyranoside, 5 mM K 4 Fe(CN) 6 , 5 mM K 3 Fe(CN) 6 , 2 mM MgCl 2 in PBS, pH6.5) for 12-18 h at 371C. Blue staining of cell nuclei identified b-galactosidase expression.
Measurement of DNA synthesis and cell proliferation
HT-29 cells in six-well plates were stimulated by 1% serum for 19 h and further incubated with [ 3 H]thymidine (0.5 mCi/ml) for 5 h. After washing with PBS three times, the cells were detached from culture plates by trypsin/ EDTA. Then radioactivities of each sample were 
Western blot analysis
Western blot analysis was carried out as described in detail. 31 Ex vivo tissue samples were immediately frozen at À801C after dissection. Frozen tissue was homogenized by thawing the samples in an appropriate volume of the lysis buffer, followed by disruption with a polytron homogenizer. After centrifugation of the sample, supernatants were assessed for protein expression of c-Jun and DN-c-Jun. Antibodies to c-Jun (sc-44; Santa Cruz, CA, USA) were used for the detection of DN-c-Jun protein.
Electrophoretic mobility shift assay
To detect DNA protein-binding reaction, EMSA) was performed as described in detail. 32 The double-stranded consensus oligonucleotide of the AP-1-binding probe, 5
0 -CGCTTGATGAGTCAGCCGGAA-3 0 , was synthesized and end labeled with [ 
Flow cytometric analysis
Cells were trypsinized, washed twice with PBS, and fixed in 70% ethanol at -201C. Before measurement, fixed cells were centrifuged at 3000 r.p.m. for 5 min and resuspended in dye combination containing 50 mg/ml RNase and 25 mg/ml PI (Sigma, St Louis, MO, USA) for DNA staining. Cellular DNA content was assessed by an FACS flow cytometer (Becton Dickinson, Mountain View, CA, USA). DNA histograms of cell distribution were obtained using ModFitLT software (Verita).
Production of xenografted tumor of HT-29 cells and its treatment with DN-c-Jun
HT-29 cells (1 Â 10 6 cells) were inoculated subcutaneously into the hind paws of BALB/cA Jcl nu/nu female mice (4-5 weeks old; CLEA Japan, Inc., Osaka, Japan). After tumor size reached a mean volume of 150 mm 3 , tumors were randomized into three groups in a blind manner; group 1, Ad-DN-c-Jun (3 Â 10 8 p.f.u.); group 2, Ad-Luciferase (Ad-Luci) (3 Â 10 8 p.f.u.); group 3, control vehicle (PBS) (n¼6). Direct injection was performed three times a week, with a total of six sessions of treatment. Each injection of purified virus was diluted in a total volume of 30 ml PBS and administered in a single pass with a 30-gauge needle, using gentle, constant infusion pressure with diethylether. Tumors were measured three times a week and immediately before each treatment, and tumor size was estimated using the following formula: length (mm) Â width (mm) Â width (mm)/2. All experimental procedures were approved by the Animal Care Committee of Osaka City University Medical School.
Immunohistochemical staining
Staining for Ki-67 was performed using rabbit polyclonal antihuman Ki-67 antigen (Dako Japan Co., Kyoto, Japan). A measure of 6-mm-thick serial cryostat sections were mounted on sialynized slide (Dako Japan Co). The sections were heated at a temperature of 951C for 45 min with a citrate acid buffer (pH 6.0) for the purpose of antigen retrieval. The primary anti-Ki-67 antibody was used at a dilution of 1:1500 and the slides were incubated in a humidified chamber at room temperature for overnight. Immunohistochemical staining was performed with the streptavidin-biotin peroxidase method (LSAB2 Kit, Dako Japan Co). Counterstaining was performed with hematoxylin. Assessment of Ki-67-positive cells was performed using light microscopy at Â 400 magnification, and labeling index was defined as the Ki-67-positive ratio determined by calculating the percentage with 42000 cancer cells per tumor.
Statistical analysis
All values are presented as means7s.e.m. Statistical significance was determined with one-way analysis of variance and Duncan multiple range test. Differences were considered statistically significant at a value of Po0.05.
